Subscribe to Entrepreneur for $5
Subscribe

Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.

By
This story originally appeared on Zacks

Lexicon Pharmaceuticals, Inc. LXRX announced the submission of a new drug application (NDA) to the FDA for sotagliflozin.

- Zacks

The NDA is seeking approval for the marketing and sale of sotagliflozin to reduce the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening condition or additional risk factors irrespective of left ventricular ejection fraction.

The regulatory body has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.

The NDA was supported by the phase III SOLOIST study results in patients with type 2 diabetes who had recently been hospitalized for worsening heart failure and phase III SCORED clinical study in patients with type 2 diabetes, chronic kidney disease and risks for cardiovascular disease.

Sotagliflozin is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-glucose co-transporter types 1 and 2 (SGLT1 and SGLT2). SGLT1 is responsible for glucose absorption in the gastrointestinal tract. SGLT2 is responsible for glucose reabsorption by the kidney.

The successful development and commercialization of the candidate will be a significant boost for the company.

It is approved in the European Union (EU) for use as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes with a body mass index ≥ 27 kg/m2, who could not achieve adequate glycemic control despite optimal insulin therapy. However, it has not yet been commercially launched.

Shares of the company have gained 11.9% in the past year against the industry’s decline of 21.9%.

Zacks Investment ResearchImage Source: Zacks Investment Research

Lexicon is also developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. It has reported results from two phase I studies of LX9211. LXRX is now conducting a phase II study of LX9211 in diabetic peripheral neuropathic pain and a second phase II study of LX9211 in post-herpetic neuralgia. The candidate has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.

Please note that LX9211 originated from its collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb BMY.

Lexicon and Bristol-Myers Squibb established a drug discovery alliance in December 2003 to discover, develop and commercialize small molecule drugs in the neuroscience field.  The company acquired the rights to LX9211 under an amendment to the neuroscience alliance. It has agreed to pay BMY development and regulatory milestones starting with the commencement of the first phase II study in the first indication.

Zacks Rank and Stocks to Consider

Lexicon currently carries a Zacks Rank #3 (Hold).  Some better-ranked stocks in the healthcare sector include GlaxoSmithKline GSK and Sarepta Therapeutics, Inc. SRPT, each carrying a Zacks Rank of 2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

GlaxoSmithKline’s estimates for 2022 earnings per share have moved north from $2.94 to $3.05 in the past 60 days. Shares of Glaxo have risen 16.9% in the year.

Earnings of Glaxo beat estimates in three of the last four quarters and missed the mark once. It has a trailing four-quarter earnings surprise of 15.3%, on average.

Estimates for Sarepta have narrowed from a loss per share of $6.95 to $4.83 for 2022 in the past 60 days.

SRPT delivered an earnings surprise of 11.06%, on average, in the last four quarters.



Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?

From inception in 2012 through November, the Zacks Top 10 Stocks gained an impressive +962.5% versus the S&P 500’s +329.4%. Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.

Be First To New Top 10 Stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

GlaxoSmithKline plc (GSK): Free Stock Analysis Report

 

Bristol Myers Squibb Company (BMY): Free Stock Analysis Report

 

Lexicon Pharmaceuticals, Inc. (LXRX): Free Stock Analysis Report

 

Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research